Gustave Roussy, Cancer Campus, Grand Paris
Clinical trials sponsored by Gustave Roussy, Cancer Campus, Grand Paris, explained in plain language.
-
New combo therapy for lung cancer passes first safety test
Disease control CompletedThis early-phase trial tested the drug everolimus (RAD001) alongside radiation therapy in 26 people with advanced non-small cell lung cancer that could not be surgically removed. The goal was to find a safe dose and check for side effects. Participants received everolimus weekly …
Phase: PHASE1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Heated chemo wash may stop colorectal cancer spreading in abdomen
Disease control CompletedThis phase 3 trial tested whether a surgical procedure called laparotomy plus heated chemotherapy (HIPEC) could improve outcomes for colorectal cancer patients at high risk of cancer spreading in the abdomen. 150 patients who had already undergone surgery and chemotherapy were ra…
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New chemo drug shows promise for tough testicular cancers
Disease control CompletedThis phase 2 trial tested a chemotherapy drug called cabazitaxel in 34 men with advanced testicular cancer that had already been treated with at least two other chemotherapies. The goal was to see if cabazitaxel could shrink tumors, including those that spread to the brain. Cabaz…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immunotherapy combo shows promise in cervical cancer trial
Disease control CompletedThis phase 2 trial tested whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with locally advanced cervical cancer. 189 participants received either the combination or standard treatment alone. The goal was to see if the combination delays …
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Robot-Assisted surgery shows promise for head and neck cancer
Disease control CompletedThis study tested a newer robotic surgery system (Da Vinci Xi) for removing head and neck tumors through the mouth. It included 100 adults with various types and stages of head and neck cancer. The main goal was to see if the procedure could be done successfully and safely. The a…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo therapy shows promise for hard-to-treat thyroid cancer
Disease control CompletedThis study tested whether combining targeted drugs (trametinib and dabrafenib) with radioactive iodine can help shrink or control advanced thyroid cancer that has stopped responding to standard radioactive iodine treatment. The trial enrolled 40 adults with specific gene mutation…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug cocktail targets tough cancers in early trial
Disease control CompletedThis early-phase study tested a combination of two drugs, temsirolimus and cetuximab, in 45 adults with advanced or metastatic solid tumors that had not responded to standard treatments. The goal was to check safety and see if blocking two cancer pathways at once could slow tumor…
Phase: PHASE1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could a targeted antibody boost chemo for kids with aggressive blood cancer?
Disease control CompletedThis phase 3 trial tested whether adding 6 doses of rituximab to standard chemotherapy improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. The study enrolled 482 high-risk patients aged 6 months to 18 years. The goal was to…
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy shows promise for kids with rare lymphoma
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy drugs (etoposide, doxorubicin, vincristine, cyclophosphamide) plus the targeted drug rituximab in 47 children and teens with primary mediastinal large B-cell lymphoma. The goal was to see how well the regimen prevented the c…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Drug combo shows promise for tough cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…
Phase: PHASE1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Sharper breast scans? new technique aims to reduce image flaws
Diagnosis CompletedThis study tested an improved version of angiomammography, a special breast X-ray that uses dye to highlight blood vessels. Researchers compared the new method to the standard SenoBright® technique in 100 women aged 40 to 70. Three radiologists reviewed the images to see which me…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
New online tool helps cancer patients get better sleep
Symptom relief CompletedThis study tested an online program to help cancer patients with insomnia. It included 348 adults with cancer who had trouble sleeping. The program used cognitive-behavioral techniques and aimed to see who might need extra help from a professional.
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Prostate cancer patients weigh in: which chemo is easier to tolerate?
Symptom relief CompletedThis study looked at whether men with metastatic prostate cancer prefer cabazitaxel or docetaxel as their first chemotherapy. 195 patients tried both drugs in sequence and then stated their preference. The goal is to see if side effects like nerve damage or fatigue influence choi…
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Phone coaching may ease fatigue after breast cancer
Symptom relief CompletedThis study tested whether a personalized telephone-based weight loss program could help reduce fatigue in overweight or obese breast cancer survivors. 220 participants who had finished active treatment for early-stage breast cancer were enrolled. The program provided motivational…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
New wheelchair gadgets aim to make hospital rides smoother for cancer patients
Symptom relief CompletedThis study tested two simple changes to hospital wheelchairs: a holder to keep IV poles attached during transport, and a more comfortable seat. Researchers wanted to see if these upgrades could shorten travel time and reduce pain for cancer patients being moved around the hospita…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated Jun 26, 2026 14:12 UTC
-
Watchful waiting: new study tracks rare tumor growth without immediate treatment
Knowledge-focused CompletedThis study followed 100 adults with a rare, non-cancerous tumor called peripheral primitive fibromatosis. Instead of treating everyone right away, doctors monitored patients closely to see how the tumors behaved over three years. The goal was to learn which factors might predict …
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Personalized medicine for kids with tough cancers: genetic profiling may point to better treatments
Knowledge-focused CompletedThis study looked at whether analyzing the DNA and RNA of children's relapsed or treatment-resistant tumors can help doctors pick targeted therapies. Researchers profiled tumors from 791 children and adolescents using advanced genetic sequencing. The goal was to see how many pati…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Researchers track skin reactions in cancer patients on newer drugs
Knowledge-focused CompletedThis study looked at skin problems caused by targeted cancer therapies. Researchers followed 141 cancer patients starting these treatments, recording any skin reactions through exams and photos. The goal was to better understand why these side effects happen and how to manage the…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Chemo's hidden toll: brain changes decades after childhood bone cancer
Knowledge-focused CompletedThis study looked at 92 adults who had chemotherapy for bone tumors (osteosarcoma or Ewing sarcoma) as children or teenagers. Researchers used surveys to measure thinking, memory, and concentration problems years after treatment. The goal was to understand which patients are most…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC